Mumbai, Maharashtra 23rd of July, 2024 : “This budget represents a pivotal move towards a Vikasit Bharat, emphasizing progress through targeted support for Garib (poor), Mahilayen (women), Yuva (the youth) and Annadata (farmers). Key focus areas include employment, skill development, MSME growth—vital for GDP and exports—and middle-class upliftment.
The full exemption of basic customs duties on three cancer treatment medicines is a notable advance, promising substantial benefits for both the pharmaceutical sector and cancer patients. With a ₹2,143 crore allocation under the Production Linked Incentive (PLI) scheme, India is set to lead globally in pharmaceuticals, with the domestic market projected to reach USD 130 billion by 2030. These steps are vital for achieving our $5 trillion GDP goal in three years and $7 trillion by 2030.
Moreover, the Prime Minister’s package, Significant funds—₹2 lakh crore for employment and skill development, and ₹1.48 lakh crore for education—are allocated to drive job creation. Enhanced focus on women’s workforce participation through dedicated hostels and targeted skilling programs is also commendable. These initiatives are expected to deliver a skilled workforce crucial for innovation and
precision industries.
The budget also prioritizes innovation, R&D, and education, fostering advancements across public and private sectors. The government’s commitment to these areas aims to boost research, enhance education quality, and develop a competent workforce. This emphasis will propel India’s technology and manufacturing sectors, positioning the country as a major global manufacturing hub.”
About Supriya Lifescience Ltd :
Established in the year 1987, Supriya Lifescience Ltd. is a global leading manufacturer of Active pharmaceutical Ingredients. Our state-of-the-art facility is certified by USFDA, EDQM, EUGMP, NMPA & Health Canada. The facility is located at Khed, District Ratnagiri and headquartered in Mumbai, India.
Supriya Lifescience Ltd. has a well-established presence in API Manufacturing with focus in products of various therapeutic segments like – Anti-Histamine, Anti- Allergics, Vitamins, Anaesthetics, Anti- Asthmatics etc.
Backed by strong R&D, 14 active USDMFs, 8 active CEPs & Worldwide compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA). Core business is driven by Ethical values and EHS standards. The company’s focus is to develop APIs and Intermediates for both Innovators, Generic companies and we also partner exclusively as CMO.
The company was founded by Dr. Satish Wagh, a first-generation entrepreneur and technocrat. Armed with technical knowledge, business acumen and an extensive experience of more than 35 years in the pharmaceutical industry, he has been instrumental for what Supriya Lifescience is today. https://supriyalifescience.com/
About The Author
More Stories
State Remembers The Contributions Of Former Union Minister Dr. Mallikarjun On His Death Anniversary.
Chief Minister Of Andhra Pradesh Meets Prime Minister.
Union Home Minister Amit Shah, Inaugurates 10,000 Newly Established M-PACS, Along With Dairy And Fisheries Cooperative Societies, In New Delhi.